Does IV therapy reduce blood microplastics?

Microplastics in the bloodstream, and a proposed “blood cleansing” approach

New research in the longevity space suggests that an IV “blood cleansing” treatment may reduce microplastics circulating in the body.

The study’s central claim is straightforward: after receiving the IV therapy, participants showed lower levels of microplastics detectable in their bloodstream compared with before treatment. That matters because microplastics have been increasingly studied for potential links to inflammation and other health effects, but hard evidence on how to reduce exposure in humans—and what clinical outcomes follow—has been limited.

What’s known from the report

• The treatment is delivered through an IV line.
• It is described as gaining popularity among longevity-focused consumers.
• The newly published findings point specifically to reduced microplastics in blood.

What’s not specified in the available story

• The underlying mechanism of how the IV therapy removes or lowers microplastics is not described.
• No information is provided on longer-term health impacts, such as whether reducing circulating microplastics translates to fewer disease events.
• Details such as trial design, participant numbers, and duration of follow-up are not included in the summary provided.

For readers, the main takeaway is that a potentially measurable biomarker—microplastics in blood—may be affected by an IV intervention. However, without additional information about safety, study rigor, and clinical endpoints, it’s premature to treat the finding as a proven pathway to meaningful health benefit.